Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Roche/Organon Teknika

This article was originally published in The Gray Sheet

Executive Summary

Roche/Organon Teknika: Ink worldwide settlement agreement to end patent litigation pending in several countries including the U.S. related to nucleic acid amplification technology. Hoffmann-La Roche first brought suit against Teknika in 1995 in The Netherlands alleging that Teknika's NASBA RNA transcription-based gene amplification system infringed Roche patents covering its PCR polymerase chain reaction gene amplification technology. Since the initial suit was filed, Dutch and German courts have ruled in Teknika's favor in the disputes ("The Gray Sheet" Sept. 16, 1996, In Brief). Terms of the settlement are not being disclosed...

You may also be interested in...



Pandemic Spotlights Tensions Between Profit And Philanthropy

The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.

Pharma R&D’s COVID-19 Scar

Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.

Advancing The Precision Mission At RSNA 2020

RSNA is the next major global medtech event to be run under a virtual format this fall. Under COVID-19, the major medtechs are finding different ways to demonstrate value, as Royal Philips explains.

UsernamePublicRestriction

Register

LL1134786

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel